Med-Chemist: vemurafenib

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label vemurafenib. Show all posts

Showing posts with label vemurafenib. Show all posts

Thursday, January 2, 2014

Vemurafenib: Result unchanged despite new data

In continuation of my update on Vemurafenib Longer survival, but also major side effects The drug approved since February 2012 can...

Monday, January 14, 2013

Melanomas that develop resistance to vemurafenib also become addicted to the drug

Vemurafenib ( marketed as Zelboraf ) is a B-Raf enzyme inhibitor developed by Plexxikon (now part of the Daiichi Sankyo group) and...

Wednesday, October 17, 2012

Drug combinations show promise against metastatic melanoma

In continuation of my update on V emurafenib .. A Phase I study in 44 patients shows that the combination of the MEK inhibitor GDC-0...

Sunday, August 21, 2011

FDA Approves Zelboraf - Potent New Melanoma Drug

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib ( PLX4032/R...

Wednesday, June 8, 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600...

View web version

Contributors

Dr. Umesh..
https://www.med-chemist.com

Powered by Blogger.